Pharmacologic modulation of orexin signaling: Impact on glucose–insulin homeostasis and potential mechanism of antidepressant action
- 1Department of Psychiatry, University of Toronto, Canada
- 2Pharmacology & Toxicology, University of Toronto, Canada
- 3University Health Network, Canada
Abstract
In addition to their canonical role in sleep–wake regulation, endogenous orexin signaling is implicated in the homeostatic control of reward and motivation, stress and arousal, and glucose–insulin metabolism. Recent research has focused on the development of orexin antagonists, notably seltorexant, as adjunctive treatments in adults with major depressive disorder (MDD). Converging evidence implicates insulin resistance in MDD pathophysiology, highlighting the need to integrate preclinical, pharmacologic, and translational evidence examining the effects of orexin signaling on glucose–insulin homeostasis. A literature review was conducted using PubMed from database inception to June 2025 to identify preclinical and clinical studies examining the metabolic effects of orexin modulation. The search string included the terms related to: orexin, glucose, metabolism, and depression. Results were synthesized qualitatively across experimental models and clinical populations. Evidence indicates that orexin signaling affects multiple aspects of metabolic homeostasis. For example, orexins affect appetitive/consummatory behavior, exert incretin-like effects on insulin release and glucagon suppression, and increase energy expenditure via morphologically transitioning white-to-brown adipose tissue. These effects are mediated through both direct (eg, inhibition of gluconeogenic enzyme expression) and indirect pathways (eg, alterations in sleep architecture and attenuation of sympathoadrenal overactivity). Orexin antagonism, therefore, exerts multi-faceted physiological effects beyond sleep regulation. The antidepressant efficacy of seltorexant in MDD is greater in persons with moderate-to-severe insomnia, while remaining clinically meaningful in persons with less severe insomnia, implicating multiple mechanisms. Modulation of glucose–insulin homeostasis represents a putative, non-mutually exclusive mechanism through which orexin antagonism may contribute to antidepressant effects.
Related
- Exploring the therapeutic potential of Erycibe paniculata (Roxb.): metabolite profiling and antimalarial, anticancer, and modulation of NF-κB signaling pathway for anti-inflammatory activities
- TRPM2 couples cell-autonomous type-I interferon signaling to pigmentation homeostasis
- SorCS2 controls Wnt signaling homeostasis during neurodevelopment by regulating Ror2 activity and trafficking
- Development and pharmacological characterization of a stable HEK293 cell model for the study of human FLT3 signaling and its pharmacological modulation
- TMEM55B Maintains Lysosomal Homeostasis and Promotes ER–Lysosome Calcium Signaling
BibTeX
@article{mcintyre2026pharmacologic,
title = {{Pharmacologic modulation of orexin signaling: Impact on glucose–insulin homeostasis and potential mechanism of antidepressant action}},
author = {Roger S. McIntyre and Sabrina Wong},
journal = {CNS Spectrums},
year = {2026},
month = jul,
doi = {10.1017/s1092852926101126},
url = {https://doi.org/10.1017/s1092852926101126},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Pharmacologic modulation of orexin signaling: Impact on glucose–insulin homeostasis and potential mechanism of antidepressant action
AU - Roger S. McIntyre
AU - Sabrina Wong
PY - 2026
DA - 2026/07/29
JO - CNS Spectrums
DO - 10.1017/s1092852926101126
UR - https://doi.org/10.1017/s1092852926101126
AB - In addition to their canonical role in sleep–wake regulation, endogenous orexin signaling is implicated in the homeostatic control of reward and motivation, stress and arousal, and glucose–insulin metabolism. Recent research has focused on the development of orexin antagonists, notably seltorexant, as adjunctive treatments in adults with major depressive disorder (MDD). Converging evidence implicates insulin resistance in MDD pathophysiology, highlighting the need to integrate preclinical, pharmacologic, and translational evidence examining the effects of orexin signaling on glucose–insulin homeostasis. A literature review was conducted using PubMed from database inception to June 2025 to identify preclinical and clinical studies examining the metabolic effects of orexin modulation. The search string included the terms related to: orexin, glucose, metabolism, and depression. Results were synthesized qualitatively across experimental models and clinical populations. Evidence indicates that orexin signaling affects multiple aspects of metabolic homeostasis. For example, orexins affect appetitive/consummatory behavior, exert incretin-like effects on insulin release and glucagon suppression, and increase energy expenditure via morphologically transitioning white-to-brown adipose tissue. These effects are mediated through both direct (eg, inhibition of gluconeogenic enzyme expression) and indirect pathways (eg, alterations in sleep architecture and attenuation of sympathoadrenal overactivity). Orexin antagonism, therefore, exerts multi-faceted physiological effects beyond sleep regulation. The antidepressant efficacy of seltorexant in MDD is greater in persons with moderate-to-severe insomnia, while remaining clinically meaningful in persons with less severe insomnia, implicating multiple mechanisms. Modulation of glucose–insulin homeostasis represents a putative, non-mutually exclusive mechanism through which orexin antagonism may contribute to antidepressant effects.
SN - 1092-8529
SN - 2165-6509
ER -